{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:00:08Z","timestamp":1792004408989,"version":"4.4.0"},"reference-count":38,"publisher":"Massachusetts Medical Society","issue":"7","license":[{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.nejmgroup.org\/legal\/terms-of-use.htm"}],"funder":[{"name":"Global Antibiotic Research and Development Partnership"},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["75A50122C00080"],"award-info":[{"award-number":["75A50122C00080"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["HHSO100201900007C"],"award-info":[{"award-number":["HHSO100201900007C"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Everest Medicines"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2024,2,15]]},"DOI":"10.1056\/nejmoa2304748","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T22:01:02Z","timestamp":1707948062000},"page":"611-622","source":"Crossref","is-referenced-by-count":142,"title":["Cefepime\u2013Taniborbactam in Complicated Urinary Tract Infection"],"prefix":"10.1056","volume":"390","author":[{"given":"Florian M.","family":"Wagenlehner","sequence":"first","affiliation":[{"name":"From Justus Liebig University, Giessen, Germany (F.M.W.); LBG Consulting, Philadelphia (L.B.G.), and Venatorx Pharmaceuticals, Malvern (P.C.M., G.M., M.D., T.H.) \u2014 both in Pennsylvania; Fortrea, Burlington, NC (P.M.); and DaneStat Consulting, Macclesfield, United Kingdom (A.D.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne B.","family":"Gasink","sequence":"additional","affiliation":[{"name":"From Justus Liebig University, Giessen, Germany (F.M.W.); LBG Consulting, Philadelphia (L.B.G.), and Venatorx Pharmaceuticals, Malvern (P.C.M., G.M., M.D., T.H.) \u2014 both in Pennsylvania; Fortrea, Burlington, NC (P.M.); and DaneStat Consulting, Macclesfield, United Kingdom (A.D.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5906-2818","authenticated-orcid":false,"given":"Paul C.","family":"McGovern","sequence":"additional","affiliation":[{"name":"From Justus Liebig University, Giessen, Germany (F.M.W.); LBG Consulting, Philadelphia (L.B.G.), and Venatorx Pharmaceuticals, Malvern (P.C.M., G.M., M.D., T.H.) \u2014 both in Pennsylvania; Fortrea, Burlington, NC (P.M.); and DaneStat Consulting, Macclesfield, United Kingdom (A.D.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Moeck","sequence":"additional","affiliation":[{"name":"From Justus Liebig University, Giessen, Germany (F.M.W.); LBG Consulting, Philadelphia (L.B.G.), and Venatorx Pharmaceuticals, Malvern (P.C.M., G.M., M.D., T.H.) \u2014 both in Pennsylvania; Fortrea, Burlington, NC (P.M.); and DaneStat Consulting, Macclesfield, United Kingdom (A.D.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"McLeroth","sequence":"additional","affiliation":[{"name":"From Justus Liebig University, Giessen, Germany (F.M.W.); LBG Consulting, Philadelphia (L.B.G.), and Venatorx Pharmaceuticals, Malvern (P.C.M., G.M., M.D., T.H.) \u2014 both in Pennsylvania; Fortrea, Burlington, NC (P.M.); and DaneStat Consulting, Macclesfield, United Kingdom (A.D.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MaryBeth","family":"Dorr","sequence":"additional","affiliation":[{"name":"From Justus Liebig University, Giessen, Germany (F.M.W.); LBG Consulting, Philadelphia (L.B.G.), and Venatorx Pharmaceuticals, Malvern (P.C.M., G.M., M.D., T.H.) \u2014 both in Pennsylvania; Fortrea, Burlington, NC (P.M.); and DaneStat Consulting, Macclesfield, United Kingdom (A.D.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Dane","sequence":"additional","affiliation":[{"name":"From Justus Liebig University, Giessen, Germany (F.M.W.); LBG Consulting, Philadelphia (L.B.G.), and Venatorx Pharmaceuticals, Malvern (P.C.M., G.M., M.D., T.H.) \u2014 both in Pennsylvania; Fortrea, Burlington, NC (P.M.); and DaneStat Consulting, Macclesfield, United Kingdom (A.D.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Henkel","sequence":"additional","affiliation":[{"name":"From Justus Liebig University, Giessen, Germany (F.M.W.); LBG Consulting, Philadelphia (L.B.G.), and Venatorx Pharmaceuticals, Malvern (P.C.M., G.M., M.D., T.H.) \u2014 both in Pennsylvania; Fortrea, Burlington, NC (P.M.); and DaneStat Consulting, Macclesfield, United Kingdom (A.D.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab591"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2018.11.018"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-020251"},{"key":"e_1_3_5_5_2","volume-title":"Antimicrobial resistance in the EU\/EEA (EARS-Net): annual epidemiological report for 2021","year":"2022","unstructured":"Antimicrobial resistance in the EU\/EEA (EARS-Net): annual epidemiological report for 2021. Stockholm: European Centre for Disease Prevention and Control, November 2022."},{"key":"e_1_3_5_6_2","volume-title":"No time to wait: securing the future from drug-resistant infections: report to the Secretary-General of the United Nations","year":"2019","unstructured":"No time to wait: securing the future from drug-resistant infections: report to the Secretary-General of the United Nations. Geneva: World Health Organization, April 29, 2019."},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00047-19"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa511"},{"key":"e_1_3_5_9_2","unstructured":"European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2022 \u2014 2020 data. Copenhagen: WHO Regional Office for Europe 2022."},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01963-19"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b01518"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlab197"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02161-21"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01281-22"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac241"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa373"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac446"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab405"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1990.149"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01053-21"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00253-22"},{"key":"e_1_3_5_22_2","unstructured":"Food and Drug Administration. Complicated urinary tract infections: developing drugs for treatment. Guidance document. June 2018 (https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/complicated-urinary-tract-infections-developing-drugs-treatment)."},{"key":"e_1_3_5_23_2","unstructured":"European Medicines Agency. Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. No. EMA\/844951 rev. 3. December 19 2018 (https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-guideline-evaluation-medicinal-products-indicated-treatment-bacterial-infections-revision-3_en.pdf)."},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780040211"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1992.03490240060037"},{"key":"e_1_3_5_26_2","volume-title":"Performance standards for antimicrobial susceptibility testing. CLSI supplement M100","year":"2019","unstructured":"Performance standards for antimicrobial susceptibility testing. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute, 2019."},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.12163"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.17034"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.0438"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.15228"},{"key":"e_1_3_5_32_2","unstructured":"AstraZeneca. Merrem IV (meropenem for injection) for intravenous use: initial U.S. approval: 1996. 2021 (https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/050706s037lbl.pdf)."},{"key":"e_1_3_5_33_2","unstructured":"Hospira. Maxipime (cefepime hydrochloride) for injection for intravenous or intramuscular use: initial U.S. approval: 1996. 2021 (https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/050679s046lbl.pdf)."},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2016.3646"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30554-1"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx139"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw378"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62220-0"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801467"}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2304748","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T22:45:50Z","timestamp":1749681950000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2304748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,15]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,2,15]]}},"alternative-id":["10.1056\/NEJMoa2304748"],"URL":"https:\/\/doi.org\/10.1056\/nejmoa2304748","relation":{},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,15]]}}}